We analyzed the components of the LFT panel, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are markers of hepatocellular damage, and gamma-glutamyl transferase (GGT), and alkaline phosphatase (ALP), which are markers of cholestasis, in COVID-19 patients at the time admission (week 0), at 1, 2 and 6 weeks following date of admission as an inpatient or outpatient depending on length of admission. This evidence concerns the gene GPT and cholestasis.